LIVERACE™ COMBO · PRODUCT OVERVIEW

Multi-Omic. Single Platform.

Two biomarkers. One platform. miR-122 + CK-18 on a single immunoassay platform for complete early-to-confirmed liver toxicity profiling across preclinical and clinical studies.



LiverAce™ COMBO

MIR-122 & CK-18

Dual Biomarker

Multi-Omics | Cross-Species

- **Two biomarkers. One platform.** miR-122 captures early hepatocellular stress while CK-18 confirms cell death. A miRNA and a protein biomarker together on a single immunoassay platform.
- **Multi-Omic liver toxicity profiling.** Comprehensive assessment combining miRNA and protein biomarkers on a single immunoassay platform, delivering the complete injury picture that PCR-free chemistry uniquely enables.
- **FDA Letter of Support.** Both miR-122 and CK-18 qualified via the IMI TransBioLine Consortium. The only PCR-free dual assay aligned with these regulatory scientific findings.

FOR RESEARCH USE ONLY · NOT FOR DIAGNOSTIC PROCEDURES

www.destinagenomics.com · info@destinagenomics.com
Av. de la Innovación 1, Office 112 · 18016 Granada, Spain
© 2026 Destina Genomica S.L.

LEARN MORE

Destina

ACCURATE LIVER TOXICITY ASSESSMENT

DRUG SAFETY · LIVER TOXICITY

PRODUCT | For Pharma & CROs

LiverAce™ COMBO

Multi-Omic. Single Platform.

For comprehensive liver toxicity monitoring, LiverAce™ COMBO brings miR-122 and CK-18 together on a single immunoassay platform. miR-122 for early hepatocellular stress and CK-18 for cell death. The **multi-omic approach** delivers complete liver toxicity profiling with one kit.



Multi-Omic approach using immunoassay workflows and platforms

The Challenge of Liver Toxicity in Drug Development.

Testing Limitations (ALT / AST)
Traditional indicators lack specificity and are released by non-hepatic tissues, leading to false safety flags that incorrectly kill viable drug candidates.

PCR's Fatal Flaw: isomiRs
PCR cannot distinguish miRNA variants (isomiRs): degradation products that create false negatives. This renders PCR unreliable for clinical miRNA diagnostics.

$ Billions LOST OPPORTUNITIES FROM FALSE POSITIVE SIGNALS AND LATE-STAGE FAILURES DUE TO HEPATOTOXICITY

#1 DILI IS THE LEADING CAUSE OF ACUTE LIVER FAILURE WORLDWIDE

KEY FEATURES

Dual Biomarker
miR-122 + CK-18 on a single immunoassay platform

Multi-Omics
miRNA + protein biomarkers on one platform


Early + Confirmed
Onset detection & injury confirmation

Micro-Sampling
Minimal sample volume for animal models

Luminex Ready
No capital investment needed

Cross-Species
Preclinical → Clinical

BIOMARKER DETECTION



Relative fold-change vs baseline · Days post hepatotoxic exposure

REGULATORY VALIDATION

✓ FDA Letter of Support for miR-122 & CK-18 — IMI TransBioLine Consortium research

✓ Only commercial single-platform PCR-free dual assay matching consortium scientific findings

COMPLETE DRUG DEVELOPMENT PROCESS — ONE ASSAY

PRE-CLINICAL | CLINICAL

In Vitro
Organoids and Cell Cultures

In Vivo
Animal Species

Clinical
Phase I → III

Same assay · Same sample type · Cross-species biomarker conservation

Destina
www.destinagenomics.com
info@destinagenomics.com
Av. de la Innovación 1, Edificio BIC
Office 112 · 18016 Granada, Spain

SCAN TO LEARN MORE

FOR RESEARCH USE ONLY

Not for diagnostic procedures

© 2026 Destina Genomica S.L.